PRODUCT INFORMATION



mStab1-1.26, InVivoPure+

Endotoxin level ≤ 1 EU/mg

Description:

mStab1-1.26, **InVivoPure+** is a mouse monoclonal antibody against **mouse Stabilin-1** (UniProt entry: Q8R4Y4), also known as **Clever-1** or **FEEL-1**. Stabilin-1 is a scavenger receptor expressed by sinusoidal endothelial cells (ECs) in the liver, lymph nodes, spleen, and bone marrow [1]. Stabilin-1 is expressed in human breast cancer and supports tumor growth [2]. It is found on subset of macrophages that mediate tissue homeostasis and is involved in liver fibrosis [3]. **mStab1-1.26** or **mStabilin-1 (clone 1.26)** is first mentioned by Schledzewski et al. (2006) [4]. To generate the antibody, a recombinant mouse stabilin-1 fragment (residues 1–710 of Q8R4Y4) fused to mouse IgG2b-Fc was purified from stably-transfected HEK293 cells and used to immunize stabilin-1 knockout mice. mStab1-1.26 recognizes stabilin-1 in rat and mouse.

The antibody is produced exclusively under serum-free conditions from hybridoma and purified through one-step purification with Protein-G affinity chromatography.

Product-ID:	AK726P+
Immunogen:	Recombinant mouse Stabilin-1 fragment from HEK 293 (residues 1–710 of Q8R4Y4, fused to mouse-IgG2b-Fc)
Host:	Mouse
Clonality:	Monoclonal
lsotype:	Mouse IgG1ĸ
Formulation:	Liquid, PBS, pH 7.4, 0.2 µm sterile filtered
Concentration:	≥ 1.00 mg/ mL
Purity:	≥ 90% (CGE, reducing conditions)
Endotoxin:	\leq 1 EU/ mg (LAL test)
Recommended Isotype Control:	Mouse IgG1- Antibody (AK3421)

The product is for research use or for further manufacturing only.

Literature:

- [1] O. Politz *et al.*, "Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues," *Biochem. J.*, vol. 362, no. 1, pp. 155–164, 2002, doi: 10.1042/0264-6021:3620155.
- V. Riabov *et al.*, "Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model," *Oncotarget*, vol. 7, no. 21, pp. 31097–31110, 2016, doi: 10.18632/oncotarget.8857.
- [3] P. Rantakari *et al.*, "Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 113, no. 33, pp. 9298–9303, 2016, doi: 10.1073/pnas.1604780113.
- K. Schledzewski *et al.*, "Lympathic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macropahages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: Implications for the assessment of lymphangiogenesis," *J. Pathol.*, vol. 209, no. 1, pp. 67–77, 2006, doi: 10.1002/path.1942.

PRODUCT INFORMATION




Product citations

- Manta CP, Leibing T, Friedrich M, Nolte H, Adrian M, Schledzewski K, et al. Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma Proteome Switch Mediating Monocyte/Macrophage Suppression. Circulation. 2022;146(23):1783–99.
- 2. Dunkel J, Viitala M, Karikoski M, Rantakari P, Virtakoivu R, Elima K, et al. Enhanced antibody production in clever-1/Stabilin-1-deficient mice. Front Immunol. 2018;9(OCT):1–11.
- 3. Karikoski M, Marttila-Ichihara F, Elima K, Rantakari P, Hollmén M, Kelkka T, et al. Clever-1/stabilin-1 controls cancer growth and metastasis. Clin Cancer Res. 2014;20(24):6452–64.
- 4. Karikoski M, Irjala H, Maksimow M, Miiluniemi M, Granfors K, Hernesniemi S, et al. Clever-1/Stabilin-1 regulates lymphocyte migration within lymphatics and leukocyte entrance to sites of inflammation. Eur J Immunol [Internet]. 2009 Dec;39(12):3477–87.
- 5. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, et al. Lympathic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macropahages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: Implications for the assessment of lymphangiogenesis. J Pathol. 2006;209(1):67–77.

PRODUCT INFORMATION



mStab1-1.26, InVivoPure+- Supplementary Data



CGE of the purified protein under reducing (red.) conditions.